Michael James Enterprises Begins Research on MJ-391, a Dronabinol Based Product for the Treatment of Anorexia Nervosa

SHORT HILLS, NJ--(Marketwired - Aug 18, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has begun research with a new Dronabinol based formulation, MJ-391 as a treatment for anorexia nervosa commonly called anorexia. MJTV now has two Dronabinol based formulations for two therapeutic treatments and will look to further expand its pipeline in the coming weeks and months.

Perhaps most convincingly, a 2014 study, published in the International Journal of Eating Disorders, was conducted on subjects with "severe" Anorexia Nervosa. Researchers administered Dronabinol to some subjects versus placebo to others, and found that those who received the cannabis-based treatment showed a significant weight gain compared to those who received the placebo. The study also noted that the medication was well tolerated and showed no serious adverse side effects.

MJTV previously completed pre-clinical trials on its Dronabinol plus formulation in the spring of 2016 with results that management believes to be much more effective than just Dronabinol alone for treating sleep apnea. Through internal research, MJTV changed the additional active ingredient that was added to the Dronabinol and has come up with a new formulation for the potential treatment of people with anorexia.

James Farinella, CEO of Michael James Enterprises, stated, "We are very excited about the current therapeutic offerings that we are developing. Just as exciting, we are very close to developing additional formulations that will increase our pipeline of products under development."

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.